CLINICAL GUIDELINES AND PRIMARY CARE
Fred Rottnek, MD; Sheryl Lyss, MD
Corresponding Author: Fred Rottnek, MD; SSM Health SLUCare Academic Pavilion
Email: Fred.Rottnek@health.slu.edu
DOI: 10.3122/jabfm.2023.230462R1
Keywords: Cannabis, Chronic Pain, Medical Marijuana, Patient Safety, Risk Assessment, Substance-Related Disorders
Dates: Submitted: 12-08-2023; Revised: 02-03-2024; Accepted: 02-12-2024
FINAL PUBLICATION: |HTML| |PDF|
Family physicians are fielding questions about cannabis—particularly for the use of cannabis for treatment of pain. Like about every substance ingested to treat medical conditions, cannabis has risks and benefits. But regarding evidence-based practice and practice-based recommendations for patients about cannabis use, the cart is in front of the horse. Cannabis use is still illegal at a federal level and a Schedule 1 drug, but most states have challenged federal law by decriminalizing or legalizing cannabis for a variety of uses. Research is difficult due to this federal status as a Schedule 1 drug since federal funding is not readily available to support research. As a result, physicians have little to no guidance about the clinical usefulness of the product. This article explores what we know and what we are learning about cannabis, and the authors provide clinical guidance for patient care based on this evidence.